Regulatory News has published 1 story about Juniper Biosciences on 15 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 15 September 2026.
This page is generated from Regulatory News’ editorial coverage of Juniper Biosciences. It is not an advertisement.
On the record
- Company
- Juniper Biosciences (private)
- Headquarters
- Bedminster, New Jersey
- Regulator
- U.S. Food and Drug Administration (CDER)
- Latest milestone
- FDA Breakthrough Therapy designation, JBS-003 (F-MISO)
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
